We’re Not Waiting – Beating Hepatitis and Cancer Together
Hepatitis B virus (HBV) is an oncogenic virus that causes liver cancer at the same rate as someone who actively smokes one pack of cigarettes per day.
Yet, we wait to treat HBV-infected patients until they develop liver disease before initiating treatment.
The WHO ‘Best Buys’ document provides recommended interventions for the prevention and control of noncommunicable diseases, and recently prevention of liver cancer through hepatitis B immunization has been included as a recommendation.
This panel discussion and Q&A will focus on the integration of the hepatitis community and hepatitis services with liver cancer and NCDs.
- Jessica Hicks, Director, World Hepatitis Alliance Panel:
- Rosie Tasker, Global Advocacy Manager, Union for International Cancer Control (UICC)
- Devin Razavi-Shearer, Associate Director, HBV/HDV, Center for Disease Analysis Foundation
- Dr Nafiisah Chotun, Programme Lead, Endemic and NTDs & RISLNET Coordinator Southern African region, Africa Centres for Disease Control and Prevention (Africa CDC)
- Wendy Wang, Deputy Director, Liver Disease Prevention and Treatment Research Foundation, Taiwan
- Milan Mishkovikj, Director, European Liver Patients’ Assocation (ELPA)